Retrophin, Inc. (RTRX)
(Delayed Data from NSDQ)
$19.72 USD
+0.61 (3.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.72 USD
+0.61 (3.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Retrophin (RTRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Retrophin (RTRX) delivered earnings and revenue surprises of 25.42% and 6.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Retrophin (RTRX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Retrophin (RTRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Retrophin (RTRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Retrophin (RTRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Retrophin (RTRX) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Retrophin (RTRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.
Retrophin (RTRX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Retrophin (RTRX) delivered earnings and revenue surprises of 102.94% and 10.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Retrophin (RTRX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.
5 Beaten-Down Biotech Stocks Set to Rebound in 2020
by Kinjel Shah
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co
Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks
by Zacks Equity Research
The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.
Top Ranked Momentum Stocks to Buy for November 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 7th
Earnings Preview: Retrophin (RTRX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Retrophin Down on Neurological Disorder Drug Study Failure
by Zacks Equity Research
Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.
Implied Volatility Surging for Retrophin (RTRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.
Retrophin (RTRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Retrophin (RTRX) delivered earnings and revenue surprises of -48.72% and 4.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Retrophin (RTRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Retrophin (RTRX) delivered earnings and revenue surprises of -75.00% and -5.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Retrophin (RTRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Retrophin (RTRX) delivered earnings and revenue surprises of -10.53% and -0.98%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Ligand (LGND) beats earnings and sales estimates for the fourth quarter of 2018 and raises 2019 guidance.
Retrophin (RTRX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Retrophin (RTRX) delivered earnings and revenue surprises of -750.00% and -8.55%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?